Molecular structure of ARQ 197, CAS Number: 905854-02-6
ARQ 197 (CAS 905854-02-6)
Application:
ARQ 197 is a novel and selective human Met inhibitor (IC50 = 0.1 µM)
CAS Number:
905854-02-6
Molecular Weight:
369.42
Molecular Formula:
C23H19N3O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
ARQ-197 is a novel and selective human Met inhibitor (IC50 = 0.1 μM).
ARQ 197 (CAS 905854-02-6) References
- ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. | Munshi, N., et al. 2010. Mol Cancer Ther. 9: 1544-53. PMID: 20484018
- ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. | Bagai, R., et al. 2010. IDrugs. 13: 404-14. PMID: 20506063
- Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation. | Qu, G., et al. 2014. Oncol Rep. 32: 341-7. PMID: 24842595
- Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. | Calles, A., et al. 2015. Mol Oncol. 9: 260-9. PMID: 25226813
- Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance. | Aoyama, A., et al. 2014. Mol Cancer Ther. 13: 2978-90. PMID: 25313010
- Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma. | Xi, WH., et al. 2015. Biochem Biophys Res Commun. 457: 723-9. PMID: 25623532
- Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1. | Lu, S., et al. 2015. Oncotarget. 6: 22167-78. PMID: 26259250
- ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. | Lath, DL., et al. 2018. PLoS One. 13: e0199517. PMID: 29924867
- ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance. | Gao, X., et al. 2019. Onco Targets Ther. 12: 1629-1640. PMID: 30881018
- Molecular targets for tivantinib (ARQ 197) and vasculogenic mimicry in human melanoma cells. | Kumar, SR., et al. 2019. Eur J Pharmacol. 853: 316-324. PMID: 30954563
Inhibitor of:
CENP-P, HGF, HGFL α, MACC1, Met, MOX-1, and TTLL7.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ARQ 197, 50 mg | sc-364408 | 50 mg | $712.00 | |||
ARQ 197, 200 mg | sc-364408A | 200 mg | $1920.00 |